Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
This analysis demonstrated TFS benefit during the 48 months since initiating nivolumab plus relatlimab compared with nivolumab alone in patients with advanced melanoma. A direct comparison between nivolumab plus relatlimab and nivolumab plus ipilimumab is needed to determine the differences between the regimens in TFS and those in traditional endpoints.
Authors
- Hussein A. Tawbi (ORCID: https://orcid.org/0000-0003-1942-851X)
- David F. McDermott (ORCID: https://orcid.org/0000-0002-2675-5095)
- Evan J. Lipson (ORCID: https://orcid.org/0000-0003-2976-0911)
- Meredith M. Regan (ORCID: https://orcid.org/0000-0002-2428-6109)
- Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
- Sandip Ranjan (ORCID: https://orcid.org/0000-0003-4342-8747)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- F Stephen Hodi
- Andriy Moshyk (ORCID: https://orcid.org/0000-0003-4895-7103)
- Jennell Palaia
- Ravi Potluri (ORCID: https://orcid.org/0000-0002-0509-2659)
- Michael B. Atkins (ORCID: https://orcid.org/0000-0003-3901-9924)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Sandeep Bilthare
- Christopher D. Lao
- A. Selvan
Institutions
- The University of Sydney (AU)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Georgetown University (US)
- Royal North Shore Hospital (AU)
- Schulman, Ronca & Bucuvalas (US)
- Shree Guru Gobind Singh Tricentenary University (IN)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- Melanoma Institute Australia (AU)
- Dana-Farber/Harvard Cancer Center (US)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Georgetown Lombardi Comprehensive Cancer Center
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-012747
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical